Growth Hormone Research Peptides
GROWTH HORMONE RESEARCH
Growth hormone research looks at how the body regulates GH release from the pituitary gland, and how that signal drives growth, metabolism, and tissue repair. Researchers use specific peptides to study two key receptor pathways involved in this process. All compounds below are sold strictly for research use only.
Peptides In This Research Area
- Tesamorelin — a GHRH analog studied for its effects on GH release
- Ipamorelin — a selective growth hormone secretagogue
- IGF-1 LR3 — a long-acting IGF-1 analog used to study downstream GH signaling
- CJC-1295 (No DAC) — a GHRH analog studied for pulsatile GH release
- CJC-1295 / Ipamorelin Blend — combines both pathways for amplified GH pulse research
- AOD-9604 — a modified GH fragment studied in metabolic research
Research Overview
GH release is controlled by two main receptors on the pituitary gland. GHRH (growth hormone releasing hormone) binds one receptor and triggers a chain reaction that boosts GH synthesis and release. Ghrelin-mimicking peptides bind a separate receptor and trigger GH release through a different signaling pathway. A third hormone, somatostatin, acts as the brake — slowing GH release when needed.
Once GH is released, most of its downstream effects happen through IGF-1, a hormone that drives cell growth and tissue repair throughout the body.
Researchers study these pathways using rodent models — sometimes with genetically modified mice that lack a specific receptor, which helps isolate exactly which pathway is responsible for an observed effect. At the cell level, pituitary cell cultures are used to directly measure how much GH is released in response to a given peptide.
The peptides used in this research generally fall into two families: GHRH analogs (like Sermorelin and CJC-1295), and growth hormone secretagogues (like Ipamorelin and GHRP-2), which mimic ghrelin. One of the most consistent findings in this field is that combining a GHRH analog with a secretagogue produces a much bigger GH pulse than either one alone — which is why these two types are so often paired in research protocols.
Common categories include GHRH analogs like Sermorelin and CJC-1295, and growth hormone secretagogues like Ipamorelin, GHRP-2, and GHRP-6 — each targeting a different receptor in the GH release pathway.
The GHRH receptor pathway and the ghrelin receptor (GHSR1a) pathway are the two most studied, along with the downstream IGF-1 signaling that follows GH release.
Freeze-drying keeps the peptide stable for long-term storage and lets researchers reconstitute it at a precise concentration right before use — important for consistent, reproducible results.
Purity is confirmed with HPLC (High-Performance Liquid Chromatography), and molecular identity is confirmed with mass spectrometry — standard practice across the research peptide industry.
Yes — pairing a GHRH analog with a secretagogue is one of the most common combinations in this field, since the two pathways work together to produce a much stronger GH pulse than either compound alone.
For Research Use Only (RUO). Not for human consumption, veterinary use, diagnostic use, or therapeutic purposes.